Intervention1: (Test Product-A) Olaparib Tablets 150 mg of Natco Pharma Limited., India: Dose: Two tablets (150 mg X 2 equals to 300mg) will be administered twice daily (total dose: 600 mg/day) from D
Sponsors
Natco Pharma Limited
Conditions
Health Condition 1: C50- Malignant neoplasm of breast
Health Condition 2: C56- Malignant neoplasm of ovary
Health Condition 3: C61- Malignant neoplasm of prostate
Unknown Phase
Bioequivalence study in Adult Male and Female Patients with Ovarian Cancer or Breast Cancer or Prostate Cancer Under Fasting Condition.
Active, not recruitingCTRI/2023/10/058337
Target: 42Updated: 2024-10-14
Bioequivalence study with Ovarian Cancer or Breast Cancer or Prostate Cancer in Adult Male and Female Patients Under Fed Condition
Active, not recruitingCTRI/2023/10/058530
Target: 42Updated: 2024-11-11